HEMK2 and prostate carcinoma: Therefore, our results not only provide a proof-of-concept for the druggability of KMT9 but also introduce KMT9 inhibitors as potential candidates for novel treatment options for currently incurable disease states such as castration- and enzalutamide-resistant prostate cancer.